 |
 |
 |
 |
 |
 |
 |
 |
Lopinavir/Ritonavir (Kaletra)
Overview
- A Clinical Overview of Lopinavir/Ritonavir (Kaletra) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Prescribing Information for Lopinavir/Ritonavir (Kaletra) Tablets (PDF) (November 2007)
From Abbott Laboratories - Prescribing Information for Lopinavir/Ritonavir (Kaletra) Capsules (PDF) (July 2007)
From Abbott Laboratories - Drug Interactions: Kaletra (August 2004)
From Project Inform - The Debate Over Kaletra (Lopinavir/Ritonavir) "Monotherapy" (August 2004)
From American Foundation for AIDS Research
News
- New Pediatric Dosing Information for Kaletra, Patients 14 Days to 6 Months and 12-18 Years of Age and Update Information on Coadministration With Midazolam (PDF) (June 23, 2008)
From U.S. Food and Drug Administration - Newly-Unsealed Documents Shed Light on Abbott Labs' 400% Norvir Price Hike (May 12, 2008)
Union, consumer groups decry Abbott for putting profits before HIV/AIDS patients' needs
In A Closer Walk: A Film by Robert Bilheimer, from Community Catalyst - Abbott Receives FDA Approval for Lower-Dose of Ritonavir for Children (November 13, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Kaletra and Accidental Overdose in Children (August 16, 2007)
Direct Healthcare Professional communication on Kaletra (lopinavir/ritonavir) solution and accidental overdose in children; available only in PDF.
From Abbott Laboratories - Abbott, FDA Warn About Possible Overdose of Antiretroviral Kaletra in Children (August 15, 2007)
The U.S. Food and Drug Administration (FDA) and Abbott Laboratories are warning health care providers to be cautious in prescribing Abbott's antiretroviral drug Kaletra to children after the death of an infant who received an accidental overdose of the drug, the AP/Forbes reports. Abbott in an Aug. 6 letter, which was posted on FDA's Web site on Tuesday, said that children should receive no more than a five milliliter dose of Kaletra. The infant who died received a 6.5 milliliter dose (AP/Forbes, 8/14). According to Dow Jones/CNNMoney.com, the infant received an oral solution of Kaletra, which contains 80 milligrams of lopinavir and 20 milligrams of ritonavir per milliliter. .
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Student Global AIDS Campaign Responds to Abbott's Decision to Reduce Price of Kaletra in Low and Middle Income Countries (April 10, 2007)
From Student Global AIDS Campaign - The State of Access to Kaletra (April-July 2006)
In GMHC Treatment Issues, from Gay Men's Health Crisis - FDA Approval of New Formulation of Kaletra (October 28, 2005)
From U.S. Food and Drug Administration - Brazil Nears New Deal With Abbott on Price of Kaletra (October 4, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Research
- Clinical Trials Using Kaletra (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - Literature Citations for Kaletra (Regularly Updated)
From U.S. National Institutes of Health - Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers. (February 14, 2008)
In Journal of Acquired Immune Deficiency Syndromes - Atazanavir Noninferior to Lopinavir in Treatment-Naive HIV-Infected People (February 6, 2008)
From The Body PRO - Lopinavir/Ritonavir Monotherapy or Plus Zidovudine and Lamivudine in Antiretroviral-Naive HIV-Infected Patients (January 30, 2008)
In AIDS - Lopinavir/Ritonavir Monotherapy Requires Strict Adherence, Studies Say (October 31, 2007)
In aidsmap.com - Another Look at TITAN and DUET: How Will They Change Clinical Practice? (July 25, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - ATAZIP: Switching Away From Lopinavir/Ritonavir (July 25, 2007)
Switching from lopinavir/ritonavir (Kaletra) to atazanavir (Reyataz)/ritonavir (Norvir) maintains virologic efficacy and leads to sustained improvements in lipid levels. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - TITAN Results (Darunavir vs. Lopinavir) (July 24, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - Efficacy and Safety of Darunavir-Ritonavir Compared With That of Lopinavir-Ritonavir at 48 Weeks in Treatment-Experienced, HIV-Infected Patients in TITAN: A Randomised Controlled Phase III Trial (July 7, 2007)
Study shows greater viral suppression among darunavir patients after 48 weeks.
In The Lancet - Kaletra-Based Regimens May Suppress Viral Load Despite Missed Doses (May 1, 2007)
In Journal of Acquired Immune Deficiency Syndromes - Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Predictors of Virologic Rebound on Lopinavir/Ritonavir Monotherapy (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Resistance Analysis of Lopinavir/Ritonavir Maintenance Therapy Study (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - The GEMINI Study: Are Saquinavir + Ritonavir and Lopinavir/Ritonavir Twins? (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection - Long-Term Lopinavir/Ritonavir Treatment and CD4+ Cell Responses (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Reducing the Dose of Lopinavir/Ritonavir Is Associated With Low-Level Viremia (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy (August 17, 2006)
In XVI International AIDS Conference - Switching From Lopinavir/Ritonavir to Unboosted Atazanavir May Yield Benefits, but Verdict Remains Uncertain (August 17, 2006)
In XVI International AIDS Conference - Treating Patients With Lopinavir/Ritonavir Alone Still Risky (August 17, 2006)
In XVI International AIDS Conference - Acid-Reducing Agents Reduce Atazanavir Drug Levels but Not Lopinavir/Ritonavir Levels (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections - During the Third Trimester of Pregnancy Lopinavir/Ritonavir Dose Should Be Increased, Study Finds (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections - Better Adherence With Once-Daily Versus Twice-Daily Lopinavir/Ritonavir: New Tablet Formulation Has Improved GI Tolerability (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Brazil, Abbott Reach Deal to Lower Price on Antiretroviral Drug Kaletra (October 12, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Brazil Again Seeks Negotiations With Abbott to Lower Price on Antiretroviral Drug Kaletra (August 19, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Coming Soon: New Lopinavir/Ritonavir (Kaletra) Formulation Allowing for 2-Tablet, Twice-Daily Dosing (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Full Virologic Suppression Can Be Maintained With Lopinavir/Ritonavir Alone; Single-Agent Therapies Worth Further Investigation (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Once-Daily Lopinavir/Ritonavir Approved for Treatment-Naive Patients (April 29, 2005)
From U.S. Food and Drug Administration - Notice of Important New Drug Interactions With Norvir, Kaletra (March 30, 2005)
New interactions noted with fluticasone (a component of Flonase nasal spray) and trazodone (Desyrel, an antidepressant).
From U.S. Food and Drug Administration - Don't Combine Fosamprenavir and Lopinavir/Ritonavir (February/March 2005)
From The Body PRO - Rash, NNRTIs and the 2NN Study (February/March 2005)
Rash appears more common among people taking nevirapine once a day.
From The Body PRO - Lopinavir/Ritonavir Monotherapy in Treatment-Naive Patients (January 2005)
Part of HIV JournalView's Top 10 Research Reports of 2004.
From The Body PRO - Kaletra Monotherapy Controversy: amfAR Publishes Overview (October 26, 2004)
In AIDS Treatment News, from AIDS Treatment News - Summary of Kaletra (Lopinavir/Ritonavir) Labeling Revisions (October 22, 2004)
Long-term efficacy and safety results from two phase II trials have now been included.
From U.S. Food and Drug Administration - Hepatitis Testing Important for HIVers Before Taking Kaletra (October 13, 2004)
From aidsmap.com - Hepatitis/HIV Coinfection Linked to Liver Complications in Kaletra Patients (September 2004)
Abstract of a study that recommends testing HIV-infected patients for HBV and HCV and measuring their baseline ALT values before lopinavir/ritonavir therapy is begun.
In HIV Medicine - Response to Lopinavir/Ritonavir in HIV-Infected Patients Coinfected With Hepatitis C and/or Hepatitis B (July 12, 2004)
In The XV International AIDS Conference, from The Body PRO - Drug Development News: Abbott (May/June 2004)
New formulations of lopinavir/ritonavir (Kaletra) and ritonavir are in the works.
In GMHC Treatment Issues, from Gay Men's Health Crisis - First Case of Potential PI Cross-Resistance Reported After Lopinavir Failure (April 29, 2004)
From aidsmap.com - Dosing Agenerase + Kaletra -- Trying to Juggle, Walk and Chew Gum All at the Same Time (March/April 2004)
A study presented at CROI 2004 bolsters support for the use of therapeutic drug monitoring to customize dosing.
In Positively Aware, from Test Positive Aware Network - Lexiva + Kaletra -- Still a Bad Idea (March/April 2004)
A short review of a study presented at CROI 2004.
In Positively Aware, from Test Positive Aware Network - Drug Monitoring, NRTI Activity Help Predict Lopinavir/Ritonavir Response in Experienced Patients (February 11, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Nelfinavir, Lopinavir/Ritonavir Appear Safe for Hepatitis C Patients (February 10, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Boosted Atazanavir Similar to Boosted Lopinavir in Treatment-Experienced Patients (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Once-Daily Lopinavir/Ritonavir as Effective as Twice-Daily, but Greater Side Effects Are Concern (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Unboosted Atazanavir Better on Insulin Sensitivity Compared to Lopinavir/Ritonavir (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - HIV Drug Kaletra Proves Effective in Five-Year Study (September 16, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Kaletra "Monotherapy" Safe and Efficacious for Treatment-Naive Patients (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Treatment Regimens Containing Efavirenz, Nevirapine or Kaletra Are the Most Potent Options for Patients Starting Therapy (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - 908 vs. Kaletra: Comparable for Experienced Patients, Not for Naive (July 28, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Kaletra: Could Upping the Dose Overcome Resistance? (July 18, 2003)
A 67 percent increase in the lopinavir/ritonavir dose was found to be far more effective than increasing only the ritonavir.
From aidsmap.com - Research From the 42nd ICAAC: High Lopinavir Levels Predict High Lipids (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Decreased Plasma Concentrations of Amprenavir and Lopinavir in HIV Patients on This Combination (July 8, 2002)
In The XIV International AIDS Conference, from The Body PRO - Antiretroviral Update: Lopinavir/Ritonavir (Kaletra) (November 2001)
In HEPP News, from Brown Medical School - Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - Efficacy of Lopinavir in Heavily Pretreated Patients (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO - A New Side Effect From Kaletra? (May 25, 2001)
From Canadian AIDS Treatment Information Exchange - FDA Issues Pancreatitis Warning for New Drug Lopinavir (March 2001)
In WISE Words, from Project Inform - Head-to-Head Study of Two Protease Inhibitors (March 2001)
To read PDF, click here
In Project Inform Perspective, from Project Inform - Kaletra: Abbott Joins the Bandwagon (Spring 2001)
Recap of Kaletra's Phase III trial results and expanded access program.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - Redirect -> http://www.aidsmap.com/en/news/D98249B4-4910-4E10-9CFE-337237389BBF.asp
- 48-Week Evaluation of Lopinavir/Ritonavir in HIV-Infected Children (April 2003)
Abstract of a recent study in the Pediatric Infectious Disease Journal finding that a liquid coformulation is safe and effective in children.
From International Association of Physicians in AIDS Care - Incidence of Resistance in a Double-Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir Plus Stavudine and Lamivudine
In Journal of Infectious Diseases - More Data on Higher-Dose Lopinavir/Ritonavir (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO
Clinical Management
Clinical Management
  |
  |